Long Wavelength Light Activated Prodrug Conjugates for Biomedical Applications

Abstract

The front cover artwork is provided by groups of Hong Yang and Gang Han at the College of Chemistry and Materials Science at Shanghai Normal University (China) and the Department of Biochemistry and Molecular Pharmacology at UMass Medical School (United States). The image shows a purple sphere transducer linked with a non‐active prodrug by photosensitive linkers. Upon irradiation with long‐wavelength light, the transducer converts the incident light to short wavelength emission to cleave the photocleavable linkers and trigger drug release. Read the full text of the Minireview, in which such developments in light‐activated prodrugs for biomedical application are reviewed, athttps://doi.org/10.1002/cptc.201800147.

Chemical and Photophysical Triggers for the Reduction of Pt(IV) Prodrugs for Anticancer Therapy

“…Ideally, the Pt(IV) complex should remain stable and therefore therapeutically inactive inside normal and cancerous tissue, but be quickly reduced into the therapeutically active Pt(II) species upon light. [23] The first photoactivatable Pt(IV) complex cis-[Pt(I) 2 (en) 2 (Cl) 2 ] (en = ethylenediamine) was reported upon introduction of iodine ligands into the coordination sphere of Pt(IV). The resulting metal complex exhibited a ligand-to-metal charge-transfer band around 400 nm.…”